{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-279648","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.223517+00:00","generated_at":"2026-06-22T04:19:10.046135+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Taysha Q3 net loss narrows to $26.3M; Astellas $50M investment extends cash runway","bullets":["Net loss $26.3M ($0.64/sh) vs $51.2M ($1.35/sh) Q3 2021; R&D expenses down to $16.4M.","Astellas invests $50M for 15% stake, options to license TSHA-120 (GAN) and TSHA-102 (Rett).","Cash $34.3M at Sept 30; plus Astellas $50M and $25.6M net from Oct offering, runway into Q1 2024.","Type B end-of-Phase 2 FDA meeting for TSHA-120 on Dec 13, 2022; regulatory update in Jan 2023.","Preliminary TSHA-102 adult data and pediatric trial start expected in H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-279648","json":"https://secwatch.observer/filing/0001193125-22-279648.json","markdown":"https://secwatch.observer/filing/0001193125-22-279648.md","text":"https://secwatch.observer/filing/0001193125-22-279648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522279648/0001193125-22-279648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522279648/d411971d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:19:10.046135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09cd6553f66c4ee7422f1c2d50d7d3b733321a6b","claim":"Taysha Gene Therapies, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, Taysha Gene Therapies, Inc. (the “ Company ”) reported financial results and business highlights for the quarter and nine months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522279648/0001193125-22-279648-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}